Scarica l'app Stockscreener
41.23
3.65%
-1.56
Dopo l'orario di chiusura:
41.23
Precedente Chiudi:
$42.79
Aprire:
$42.93
Volume 24 ore:
1.11M
Relative Volume:
0.98
Capitalizzazione di mercato:
$2.45B
Reddito:
$66.05M
Utile/perdita netta:
$-422.60M
Rapporto P/E:
-5.6861
EPS:
-7.251
Flusso di cassa netto:
$-384.73M
1 W Prestazione:
+9.71%
1M Prestazione:
+42.76%
6M Prestazione:
+45.12%
1 anno Prestazione:
+4.30%
Intervallo 1D:
$40.26
$42.93
Intervallo di 1 settimana:
$36.77
$44.09
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
41.23 | 2.45B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Reiterato | H.C. Wainwright | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs - Stock Titan
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - AOL.com
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week - AOL.com
Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? - Yahoo Finance
Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease - Yahoo Finance
Agios gains FDA priority review for Pyrukynd label expansion - MSN
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up - The Globe and Mail
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $41 to $54 - Moomoo
Eli Lilly Stock Forecast: Why Foundayo Access Could Push LLY Past $1,000 by Late 2026 - finance.biggo.com
What Is Driving Focus on Agios Pharmaceuticals (NASDAQ:AGIO)? - Kalkine Media
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $41 - Moomoo
AGIO Stock Jumps As Mitapivat Trial Data Fuels Bullish Targets - timothysykes.com
After receiving priority review designation from the FDA for its sickle cell disease treatment, Agios Pharmaceuticals, Inc. shares surged by 12.4%. - Bitget
Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target - TechStock²
Why Is Agios Pharma Stock Soaring Tuesday? - Benzinga
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) - The Motley Fool
AGIO Maintained by RBC Capital -- Price Target Raised to $32 - GuruFocus
Agios Pharmaceuticals (AGIO) Receives Priority Review from FDA f - GuruFocus
Agios Pharmaceuticals (AGIO) Sees 13.5% Surge - GuruFocus
AGIO Stock Jumps As Mitapivat Sickle Cell Data Fuels Hype - StocksToTrade
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) - The Motley Fool
AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism - Stocktwits
Agios Pharmaceuticals (AGIO) Secures FDA Priority Review for Mit - GuruFocus
Saol Therapeutics resubmits NDA for SL1009 - The Pharma Letter
Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Treatment - marketscreener.com
BofA Securities Adjusts Price Target on Agios Pharmaceuticals to $46 From $40, Maintains Buy Rating - Moomoo
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga
Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $42.62, Implies 14% Upside - TradingView
FDA accepts Agios sNDA for mitapivat in sickle cell disease - Investing.com
AGIO Maintained by B of A Securities -- Price Target Raised to $46 - GuruFocus
Agios Pharmaceuticals (AGIO) Gains FDA Priority Review for Pyruk - GuruFocus
Agios Says US FDA Grants Priority Review for Mitapivat to Treat Sickle Cell Disease - Moomoo
Agios Pharmaceuticals (AGIO) Receives FDA Priority Review for Mi - GuruFocus
RBC Capital Adjusts Agios Pharmaceuticals PT to $32 From $28, Maintains Sector Perform Rating - marketscreener.com
FDA accepts Agios sNDA for mitapivat in sickle cell disease By Investing.com - Investing.com Canada
FDA puts Agios' sickle cell drug on fast track to Nov. 1 review date - Stock Titan
Pulling the plug on cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma - Stockhouse
Price to sales forward of Agios Pharmaceuticals, Inc. – MUN:8AP - TradingView
Price to sales forward of Agios Pharmaceuticals, Inc. – DUS:8AP - TradingView
The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily
Price to book forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO - TradingView
AGIOAgios Pharmaceuticals Inc Latest SEC Filings - Finviz
Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock By Investing.com - Investing.com Nigeria
Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock - Investing.com
D. E. Shaw reports 3.03M-share stake in Agios (AGIO) - Stock Titan
Agios (NASDAQ: AGIO) CMO nets shares after RSU vesting and tax sale - Stock Titan
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gheuens Sarah - Moomoo
AGIO (NASDAQ: AGIO) affiliate notifies plan to offer 4,007 shares via broker - Stock Titan
Agios Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Agios Pharmaceuticals Inc Azioni (AGIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Sale |
37.56 |
4,007 |
150,503 |
84,645 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):